MCM
VKTX icon

Moore Capital Management’s Viking Therapeutics VKTX Stock Holding History

Moore Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$554K – 548
2023
Q3 		$554K Buy
+50,000
New +$715K 0.01% 333
2023
Q1 		– Sell
-100,000
Closed -$940K – 591
2022
Q4 		$940K Buy
+100,000
New +$446K 0.02% 339
2018
Q3 		– Sell
-100,000
Closed -$949K – 347
2018
Q2 		$949K Buy
+100,000
New +$665K 0.02% 218

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's VKTX Position: Q4 2023 in Review

Moore Capital Management sold out of Viking Therapeutics (VKTX) in Q4 2023, closing a stake of 50,000 shares — an estimated $554K sold.

Moore Capital Management first reported a position in VKTX in Q2 2018 and held it in 3 quarters. The position peaked at $949K in Q2 2018. 197 funds tracked by Wall St. Rank hold VKTX as of Q4 2023.

  • Moore Capital Management reported no remaining Viking Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 50,000 Viking Therapeutics shares in Q4 2023, an estimated $554K.
  • Moore Capital Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 3 quarters.
  • Moore Capital Management's Viking Therapeutics position peaked at $949K in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.